READY FOR RINVOQ?
Moderate to severe UC, breakthrough symptoms on anti-integrin
Prior conventional therapy: 5-ASA, oral corticosteroids
- Diagnosed with extensive colitis 6 years ago and started on conventional therapy
- Prescribed corticosteroids to manage flare-ups (has needed 2 courses in the past year)
Prior biological therapy: TNFi (adalimumab)
- Started anti-TNF treatment 3.5 years ago, discontinued due to loss of response
Current biological therapy: anti-α4β7 integrin
- Switched to anti-α4β7 integrin 9 months ago but experiencing symptoms
- Bio-IR*
- Abdominal pain, unpredictable flare-ups with occasional joint pain
- Occasional bowel urgency: elevated stool frequency (1–2 more than normal per day) with rectal bleeding most of the time
Clinical workup revealed moderate to severe disease activity, confirmed by colonoscopy:
- Elevated fecal calprotectin (2123 mg/kg); colonoscopy showed moderate to severe erythema, friability, and erosions (adapted Mayo score† 8; endoscopic subscore 3)
- hs-CRP: 5.4 mg/L
*Prior treatment failure to at least 1 biologic therapy. †The Adapted Mayo Score evaluates UC stage, based on 4 parameters: stool frequency, rectal bleeding, endoscopic evaluation, and Physician’s global assessment. Each parameter of the score ranges from 0 (normal or inactive disease) to 3 (severe activity). A score of 0–2 indicates remission, 3–5 mild activity, 6–10 moderate activity, and >10 severe activity.1,2
Note for affiliates: If these patient profile characteristics are used, the following references should be added and renumbered in sequential order within an affiliate's CLM: References: 1. Rutgeerts P, Sandborn WJ, Feagan BG, et al. N Engl J Med. 2005;353(23):2462-2476. doi:10.1056/NEJMoa050516 2. Schroeder KW, Tremaine WJ, Ilstrup DM. N Engl J Med. 1987;317(26):1625-1629. doi:10.1056/NEJM198712243172603
Affiliates should also add definitions to abbreviations page in the CLM: bio-IR: biologic inadequate response; TNFi: tumor necrosis factor inhibitor